Beta Thalassemia HBB Full Gene Analysis (Single) in UAE | 1000 AED | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited, DHA-compliant Sanger Sequencing.

Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.

Clinical Guidance: Complimentary telephonic post-test clinical guidance from our medical genetics team.

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Pre-Test Requirement (DHA/MOHAP Standard): A doctor’s prescription is required. Exemptions: Prescription is not required for surgery, pregnancy, or individuals planning to travel abroad.

Test Overview & Methodology

Beta Thalassemia HBB Full Gene Analysis (Single) determines the complete DNA sequence of the beta-globin gene using gold-standard Sanger chemistry, detecting all clinically significant point mutations, small deletions, and splice-site variants. This test provides definitive molecular confirmation of beta-thalassemia carrier status or disease. Results must be interpreted in conjunction with complete blood count, hemoglobin electrophoresis, and family history.

Feature	Our Test (Full Gene Sanger)	Closest Alternative (Targeted Mutation Panel PCR)
Diagnostic Precision	Identifies all pathogenic variants across entire gene, including rare familial mutations	Detects only predefined common mutations; may miss up to 15% of causative variants in UAE population
Methodology	Sanger Sequencing (Gold Standard, DHA/MOHAP approved)	ARMS-PCR or Reverse Dot Blot
Turnaround Time	8–10 working days	5–7 working days

Physician Insight & Safety Protocols

"The HBB full gene analysis is the gold standard for confirming beta-thalassemia carrier or affected status. A genetic result should never be used in isolation; it requires correlation with hematological parameters and pedigree analysis. Every patient must receive post-test genetic counseling to understand recurrence risks and reproductive options."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Advisory: Medication Continuation

⚠️ Medication Warning

Do not discontinue prescribed medication (e.g., iron chelators, folic acid) without consulting your physician. Genetic results do not replace ongoing clinical management.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Active uncontrolled bleeding disorder; severe anemia (Hb < 7 g/dL) requiring immediate transfusion; inability to provide informed consent. Patients with known severe hemophilia must inform the phlebotomist before sample collection.
Emergency Red Flags: If you experience sudden severe pallor, fainting, shortness of breath at rest, or chest pain after blood draw, seek emergency medical attention immediately. This test is not for self-diagnosis; interpretation requires a licensed physician.
Clinical Safety & Consent: All clinical procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.

Patient FAQ & Clinical Guidance

1. How does full gene analysis differ from a targeted mutation panel?

Full gene sequencing by Sanger covers all coding regions and splice sites, ensuring no rare mutation is missed, unlike panels that only check common variants. This test is recommended for families with suspected rare mutations or inconclusive panel results.

2. Is this test suitable for prenatal carrier screening?

Yes, this is the definitive option for couples planning pregnancy; it identifies both common and rare HBB mutations vital for genetic counseling. Confirm with your obstetrician or genetic counselor for optimal timing.

3. What does the 8–10 day turnaround time include?

The timeline covers sample transport, DNA extraction, Sanger sequencing, bioinformatics analysis, and a double-reviewed clinical report authored by a consultant medical geneticist. Expedited options are available upon request.

UAE Regulatory & Data Privacy Adherence

This test and its associated data handling are fully compliant with:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
Federal Decree-Law No. 4 of 2016 on Medical Liability
Dubai Health Authority (DHA) regulations for genetic testing laboratories

Patient genetic data is encrypted, access-controlled, and never shared without explicit consent. All laboratory processes adhere to ISO 9001:2015 standards.

Clinical & Logistical Metadata

Test Name	Beta Thalassemia HBB Full Gene Analysis (Single)
Price (AED)	1000
Turnaround Time	8–10 working days
Sample Type / Matrix	Peripheral Whole Blood
Methodology Used	Sanger Sequencing (Gold Standard)
ICD-10-CM Code	D56.1 (Beta thalassemia)
LOINC Code	21656-4 (Hemoglobin beta chain gene analysis)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE